BRIEF-Novo Nordisk Files For Regulatory Approval In The US

by Reuters
Wednesday, 20 January 2021 15:12 GMT

Jan 20 (Reuters) - Novo Nordisk A/S:

* NOVO NORDISK FILES FOR REGULATORY APPROVAL IN THE US OF ONCE-WEEKLY SEMAGLUTIDE 2.0 MG FOR THE TREATMENT OF TYPE 2 DIABETES

* SUBMISSION OF A LABEL EXPANSION APPLICATION TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR EXISTING MARKETING AUTHORISATION FOR OZEMPIC(®), A ONCE-WEEKLY GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE, TO INTRODUCE A NEW DOSE OF 2.0 MG

* SUBMISSION IS BASED ON RESULTS FROM SUSTAIN FORTE TRIAL Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Our Standards: The Thomson Reuters Trust Principles.